Potential therapeutic benefit of novel DDAH inhibitors for the treatment of endotoxemia by Nandi, M. et al.
  
 
University of Westminster Eprints 
http://eprints.wmin.ac.uk 
 
Potential therapeutic benefit of novel DDAH inhibitors for the 






Caroline L. Smith* 
R. Stidwell 
James M. Leiper 
Patrick Vallance 
 
University College London, UK 
 
* Caroline L. Smith now works within the School of Biosciences, University of 
Westminster 
 
This is an electronic version of an article published in Vascular Biology and 
Medicine: 3rd European Meeting, Hamburg, September 2005, abstracts. 
Journal of Vascular Research (42, supplement 2). Karger, Germany, pp. 103. 






The Eprints service at the University of Westminster aims to make the research 
output of the University available to a wider audience.  Copyright and Moral Rights 
remain with the authors and/or copyright owners. 
Users are permitted to download and/or print one copy for non-commercial private 
study or research.  Further distribution and any use of material from within this 
archive for profit-making enterprises or for commercial gain is strictly forbidden.    
 
 
Whilst further distribution of specific materials from within this archive is forbidden, 
you may freely distribute the URL of the University of Westminster Eprints 
(http://eprints.wmin.ac.uk). 
 
In case of abuse or copyright appearing without permission e-mail wattsn@wmin.ac.uk. 
In: Vascular Biology and Medicine: 3rd European Meeting, Hamburg, September 2005, 
abstracts. Journal of Vascular Research (42, supplement 2). Karger, Germany, 103. 
ISBN 3805580355  
Potential therapeutic benefit of novel DDAH inhibitors for the treatment 
of endotoxemia. 
M. Nandi, S. Rossiter, B. Torondel, M. Malaki, C. Smith, R. Stidwill, J. Leiper, 
P. Vallance University College London, London, GB. 
 
INTRODUCTION During the onset of sepsis, the induction of inducible nitric 
oxide synthase (iNOS) and the subsequent generation of large amounts of 
nitric oxide (NO) is thought to be partly responsible for the marked 
hypotension ultimately leading to inadequate organ perfusion and 
cardiovascular collapse. A potential therapeutic target in sepsis is inhibition of 
excess NO generation, although to date, direct NOS inhibition has proved 
unsuccessful. Asymmetric dimethylarginine (ADMA) is an endogenously 
occurring competitive inhibitor of NOS. ADMA is subject to hydrolysis 
catalysed by the enzyme dimethylarginine dimethylaminohydrolase (DDAH). 
We have developed novel DDAH inhibitors to pharmacologically elevate 
endogenous ADMA levels as a potential therapeutic intervention in the 
treatment of sepsis. 
 
METHODS Novel inhibitors of DDAH were synthesised and characterised 
using: in vitro enzyme assays and in vitro and in vivo rat models of acute 
endotoxemia. 
 
RESULTS Isolated enzyme studies revealed that the novel DDAH inhibitor L-
291 resulted in a concentration dependent inhibition of DDAH activity whilst 
having no direct effect on NOS activity. In vitro functional studies using 
isolated rat aorta demonstrated that L-291 reversed the iNOS mediated 
dilatation produced by 
LPS treatment by 16% ± 4.4 at 100uM and 25%± 4.1 at 200uM. 
In anaesthetised rats, a bolus dose of LPS induces iNOS mediated 
vasodilatation resulting in a gradual fall in blood pressure. Administration of L-
291 in LPS treated rats elevated circulating ADMA levels when compared with 
saline control 
(2.42 ± 0.12uM vs. 1.17±0.09uM) and attenuated the fall in blood pressure. 
 
CONCLUSION We have generated a novel highly selective DDAH inhibitor, 
which elevates circulating ADMA levels in vivo. In a rat model of acute 
endotoxemia DDAH inhibition attenuates iNOS mediated hypotension and 
stabilises blood pressure. 
 
